Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Comparative Risk of Adverse Cardiovascular Outcomes With Zanubrutinib Versus Ibrutinib in B-Cell Malignancies: A Large Real-World Propensity-Matched Analysis.

The American journal of cardiology·2026

Same author

Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.

Signal transduction and targeted therapy·2026

Same author

BIO26-045: nSIGHT: A Research Discovery Platform for Visualization, Integration and Retrospective Analysis of Multimodal Clinical Data.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Infusion-Related Reactions from Immune Checkpoint Inhibitors in Solid Tumors: A Proportional and Network Meta-Analysis.

Targeted oncology·2026

Same author

nSIGHT™: A Data Discovery Platform for Visualization, Integration and Retrospective Analysis of Multimodal Clinical Research Data.

medRxiv : the preprint server for health sciences·2026

Search research articles

Related Experiment Video

Updated: Feb 24, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Challenges faced when identifying patients for combination immunotherapy.

Marc S Ernstoff¹, Shipra Gandhi¹, Manu Pandey²

¹Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.

Future Oncology (London, England)

|August 25, 2017

Summary

Immune checkpoint inhibitors like anti-CTLA4 antibodies have revolutionized cancer treatment. Selecting the optimal combination therapy for each patient remains a key challenge in immuno-oncology.

Keywords:

atezolizumab avelumab immune checkpoint inhibitors immunotherapy ipilimumab nivolumab

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

Discrimination of Seven Immune Cell Subsets by Two-fluorochrome Flow Cytometry

Discrimination of Seven Immune Cell Subsets by Two-fluorochrome Flow Cytometry

Published on: March 5, 2019

Related Experiment Videos

Last Updated: Feb 24, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

Discrimination of Seven Immune Cell Subsets by Two-fluorochrome Flow Cytometry

Discrimination of Seven Immune Cell Subsets by Two-fluorochrome Flow Cytometry

Published on: March 5, 2019

Area of Science:

Immunology
Oncology
Medical Science

Background:

The discovery of CTLA-4 blockade in 1996 showed potential for enhancing anti-tumor responses in mice.
Clinical validation of anti-CTLA4 antibodies, like ipilimumab, led to FDA approval and established checkpoint inhibitors in cancer therapy.
Numerous immune-modulating agents are now available, prompting research into combination therapies.

Purpose of the Study:

To review current strategies for selecting optimal combination immunotherapies.
To address the challenge of personalized combination therapy selection in immuno-oncology.

Main Methods:

Review of existing literature and clinical data on immune-modulating agents.
Analysis of current approaches to combination therapy selection.

Main Results:

Anti-CTLA4 antibodies have demonstrated significant clinical efficacy.
The development of multiple immune checkpoint inhibitors has created opportunities for combination therapies.
Identifying the best combination for individual patients is a complex but critical area of research.

Conclusions:

Optimizing combination immunotherapy requires careful patient selection.
Further research is needed to establish clear guidelines for combination therapy selection.
Personalized approaches are essential for maximizing the benefits of immuno-oncology.